Parkinson's Disease Dementia Clinical Trial
Official title:
A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
This is a randomized, double blinded, placebo-controlled Phase II study to investigate the efficacy and safety of ceftriaxone in patients with mild to moderate Parkinson's disease dementia (PDD).This study will enroll approximately 106 patients to have up to 84 evaluable subjects, and conduct in Chung Shan Medical University Hospital, National Taiwan University Hospital, Kaohsiung Chang Gung Memorial Hospital, China Medical University Hospital, Changhua Christian Hospital, and Taipei Veterans General Hospital.
Parkinson's disease (PD) is a common neurodegenerative disorder that can cause significant disability and decrease quality of life. It is a chronic and progressive disease which means the symptoms become worse over time. Parkinson's disease dementia (PDD) is a decline in thinking and reasoning that develops in many people living with PD at least a year after diagnosis. An estimated 50 to 80 percent of patients with PD eventually experience dementia as the disease progresses. Ceftriaxone is a kind of antibiotics, which has been marketed in many countries. This is the first time for ceftraxone treatment on PDD patient. The primary objective of this Phase II study is to evaluate the improvement of cognitive function in PDD patients with ceftriaxone administration. This study will enroll approximately 106 patients, and conduct in multiple hospitals in Taiwan. Recruitment number of each site will be adjusted according to its enrollment status under the competitive enrollment model. Subjects will receive either ceftriaxone or placebo in a 1:1 ratio. One of the subjects' main caregiver should be involved to get the information of function of daily life and help to complete scale evaluation. The study lasts about 33 weeks, during which eligible patients will be given 1 g/day/dose of ceftriaxone or placebo via injection 3 doses every cycle (2 weekly cycle), for a total of 16 cycles. And the subjects can choose to get injection either in the clinical site or in their house. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02910102 -
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
|
Phase 2 | |
| Terminated |
NCT02871427 -
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
|
Phase 2 | |
| Active, not recruiting |
NCT02914366 -
Ambroxol as a Treatment for Parkinson's Disease Dementia
|
Phase 2 | |
| Completed |
NCT02281474 -
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
|
Phase 1 | |
| Completed |
NCT02708186 -
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
|
Phase 2 | |
| Completed |
NCT00623103 -
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
|
Phase 3 | |
| Completed |
NCT00855686 -
Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies
|
Phase 4 | |
| Recruiting |
NCT04844060 -
Cerebro Spinal Fluid Collection (CSF)
|
||
| Completed |
NCT02702102 -
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
|
Phase 2 | |
| Completed |
NCT01102582 -
An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia
|
N/A |